HUMALOG 100 UNIT
INSULIN LISPRO : 100 UNIT · DIN 02229704 · ELI LILLY CANADA INC
Health Canada status: MARKETED
What is HUMALOG?
HUMALOG 100 UNIT contains INSULIN LISPRO : 100 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02229704, held by ELI LILLY CANADA INC, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR ; SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 17-Sep-1997. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HUMALOG used for?
Treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis and for the initial stabilization of diabetes mellitus.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02229704 |
|---|---|
| Brand name | HUMALOG |
| Generic / active ingredient | INSULIN LISPRO : 100 UNIT |
| Manufacturer | ELI LILLY CANADA INC |
| Strength | 100 UNIT |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR ; SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | A10AB04 INSULIN LISPRO |
| AHFS class | 68:20.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Sep-1997 |
| Original market date | 1996-11-27 00:00:00 |
How is it administered?
Dosage determined by physician. HUMALOG should be given within 15 minutes before a meal (or within 20 minutes after starting). HUMALOG 200 units/mL is for patients requiring >20 units/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (refers to Part III), but generally requires refrigeration.
How is it supplied?
Vials, cartridges, and prefilled pens (KwikPen). (Specific pack sizes like 'bottles of 100' not explicitly detailed in provided text summary).
Contraindications
Contraindicated during episodes of hypoglycemia and in patients sensitive to insulin lispro or any of the excipients.
Warnings and precautions
Hypoglycemia is the most common adverse effect. HUMALOG 200 units/mL must not be used in pumps or mixed with other insulins. Do not transfer 200 units/mL insulin to a syringe.
What can be used instead?
Other Canadian products sharing ATC code A10AB04 INSULIN LISPRO. 8 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADMELOG | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02469901 |
| ADMELOG | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02469898 |
| ADMELOG SOLOSTAR | 100 UNIT | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02469871 |
| HUMALOG | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | MARKETED | DIN 02470152 |
| HUMALOG (CARTRIDGE) | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | MARKETED | DIN 02229705 |
| HUMALOG (KWIKPEN) | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | MARKETED | DIN 02403412 |
| HUMALOG 200 UNITS/ML KWIKPEN | 200 UNIT | SOLUTION | ELI LILLY CANADA INC | MARKETED | DIN 02439611 |
| HUMALOG PEN | 100 UNIT | LIQUID | ELI LILLY CANADA INC | CANCELLED POST MARKET | DIN 02241283 |
| LIPRELOG | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | CANCELLED PRE MARKET | DIN 02513374 |
| LIPRELOG | 100 UNIT | SOLUTION | ELI LILLY CANADA INC | CANCELLED PRE MARKET | DIN 02513331 |
Who else supplies INSULIN LISPRO worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN LISPRO appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.